

Circulate

Circulating Cancer Biomarkers

Conference Day One
Tuesday, 18th November

8.00 Registration, Coffee, Networking

9.00 Chairman's Opening Remarks

Scott Kahn, CSO, Oncostem Biotherapeutics; International Cancer Advocacy Network; Columbia University

Advances in Circulating Cancer Biomarkers

9.10 The Challenges Of Bringing Circulating Cancer Biomarkers Into A Clinical Laboratory

Rajyalakshmi Luthra, Professor and Technical/Scientific Director, Molecular Diagnostic Laboratory, M.D. Anderson Cancer Centre

9.40 Protein Multiplex Arrays To Identify Blood-Based Biomarkers

Andrew Nixon, Associate Professor, Department of Medial Oncology, Duke University

10.10 Molecular Targets Of CTCs And New Perspectives In The Research For Early Cancer Biomarkers

Alexandre Tavartkiladze, Professor, Medical Oncologist, Georgian Cancer Research Centre

10.40 Morning Refreshments & Speed Networking

<u>CTC Innovation & Developments</u>	<u>Novel Circulating Nucleoproteins</u>
<i>Predictive Uses for CTCs</i>	<i>Identifying and Targeting Novel Circulating Biomarkers</i>
11.40 Isolation and Characterization of Circulating Melanoma Cancer Cells by Size Filtration and Fluorescent In Situ Hybridization <i>Masahiko Yanagita, Postdoctoral Fellow, Dana-Farber Cancer Institute</i>	11.40 Biofluid Extracellular Vesicles RNA As A Source Of Brain Tumor Biomarkers <i>Leonora Balaj, Biomarker Researcher, Massachusetts General Hospital</i>
12.10 Identification Of Metastatic Precursors Within Circulating Tumor Cells In Breast Cancer Patients <i>Nicola Aceto, Postdoctoral Fellow, Harvard Medical School</i>	12.10 Circulating microRNAs As 'Liquid Biopsies' In Diagnostics And Therapy <i>Anton Wellstein, Professor, Georgetown University</i>
12.40 The Role Of The Pathologist In The Measurement Of Circulating Tumor Cells (CTCs): A Pathologist's Perspective <i>Malini Harigopal, Associate Professor, Yale University</i>	12.40 Large Oncosomes And Other Extracellular Vesicles: A Source Of Cancer-Derived Circulating Markers <i>Dolores Di Vizio, Associate Professor, Cedars-Sinai Medical Center/UCL</i>

1.10 Lunch & Networking



<i>Molecular Characterization of CTCs</i>	<i>The Future Of Cancer Biomarkers</i>
2.10 Characterization Of Prostate Cancer CTCs By 3D Nuclear Telomere Imaging <i>Sabine Mai, Director, Genomic Centre for Research and Diagnosis</i>	2.10 Circulating CAF Measured In Multiple Phase II Clinical Studies Evaluating Lenvatinib, A Multiple-Receptor Tyrosine Kinase Inhibitor <i>Mark Matijevic, Biomarkers and Personalized Medicine, Eisai</i>
<i>CTC Isolation Techniques and Technologies</i>	<i>Clinical Relevance of ctDNA</i>
2.40 Microfluidic Separation Of Circulating Tumor Cell Subpopulations <i>Shana Kelley, Professor, University of Toronto</i>	2.40 Free Circulating DNA Methylation As A Biomarker For High-Grade Serous Ovarian Cancer <i>Goli Samimi, Head, Ovarian Cancer Research Group, Garven Institute of Medical Research</i>
3.10 Nanovelcro CTC Assays For Cancer Staging And Mutational Analysis <i>Hsian-Rong Tseng, Professor, UCLA</i>	3.10 Integrating cfDNA genotyping into routine lung cancer care: Diagnostic, response, and resistance <i>Geoffrey Oxnard, Thoracic Oncology, Dana-Farber Cancer Institute</i>

3.40 Afternoon Refreshments

4.10 Circulating Roundtables

Complimentary uses of CTCs and Circulating Nucleic Acid

- How do you envision seeing both technologies working together?
- What could the future of circulating cancer biomarkers look like?

Experimental Design

- How do we analyze the data that we do have?
- What would the ideal experimental design look like?

Novel Technologies

- What new technologies would you like to see?
- How can we improve existing technologies?

Unified Databases

- What would a unified database look like?
- How would it improve success in the industry?

Moderators:

Katharina Pachmann, Professor, University of Jena


Matthew Marton, Director, Clinical Genomics, Merck

Anton Wellstein, Professor, Georgetown University

5.10 Chairman's Closing Remarks

Scott Kahn, CSO, Oncostem Biotherapeutics; International Cancer Advocacy Network; Columbia University

5.15 Close of Day 1



Circulate

Circulating Cancer Biomarkers

Conference Day Two
Wednesday, 19th November

8.00 Breakfast and Networking

9.00 Chairman's Opening Remarks

Scott Kahn, CSO, Oncostem Biotherapeutics; International Cancer Advocacy Network; Columbia University

9.10 Circulating Round Table Intelligence

*Katharina Pachmann, Professor, University of Jena
Matthew Marton, Director, Clinical Director, Merck
Anton Wellstein, Professor, Georgetown University*

9.40 Validation and Clinical Readiness for Isolation of Circulating Tumor Cells from Sarcoma Patient Blood Specimens

Robert Kinders, Head Pharmacodynamics Assay Section, Frederick National Laboratory for Cancer Research

10.10 Role Of Epithelial-To-Mesenchymal (EMT) Transition In Circulating Tumor Cell (CTC) Generation And Metastasis In Prostate Cancer

Alison Allan, Assistant Director, Pamela Greenaway Kohlmeier Translational Breast Cancer Unit

10.40 Morning Refreshments & Networking

Genomic Analysis

11.10 Single Genomic Analyses of Circulating Tumor Cells

Sunney Xie, Mallinckrodt Professor of Chemistry and Chemical Biology, Harvard University

11.40 Single-Tube Enrichment Of Mutations In Cancer Gene Panels From Circulating DNA, Using COLD-PCR Prior To Targeted Amplicon Re-Sequencing

Mike Makrigiorgos, Professor, Radiation Oncology, Dana-Farber Cancer Institute

12.10 EGFR Mutation Detection In ctDNA From NSCLC Patient Plasma; Comparison Of Leading Technologies To Support The Clinical Development Of AZD9291

Kenneth Thress, Oncology Translational Scientist, AstraZeneca

12.40 Lunch & Networking

Progressing to Clinical Trials

2.00 Practical Considerations For Incorporating CTC Related Endpoints Into Clinical Trials

Minetta Liu, Associate Professor, Director, Mayo Clinic



2.30 Potential Circulating Biomarkers Of Response And Escape For Targeted Therapy

Dan Duda, Associate Professor, Edwin. L Steele Laboratory for Tumor Biology, Massachusetts General Hospital

3.00 CTC Capture And Molecular Analysis: Lessons From Clinical Trials

Edith Szafer-Glusman, Research Scientist, Circulating Tumor Cells, Genentech

3.30 Afternoon Refreshments

4.00 An apparatus to count Circulating Tumor Cells, with increased throughput and decreased cost, based on microfluidic cell isolation and metabolism measurements (Warburg effect).

Giacinto Scoles, Principal Investigator, University of Udine

4.30 Key Trends For The Future Of Biomarker Research

This is your opportunity to discuss any burning questions you have and have a whole host of experts from the audience provide different perspectives.

- The future and potential of circulating cancer biomarkers
- Where will we be in the next 3, 6, 12 months?
- What breakthroughs or discoveries need to happen for success in the field?

5.00 Chairman's Closing Remarks

Scott Kahn, CSO, Oncostem Biotherapeutics; International Cancer Advocacy Network; Columbia University

5.10 Close of Congress